KLINIChESKAYa VZAIMOSVYaZ' OSTEOPOROZA I ATEROSKLEROZA


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article considers the mechanisms of osteoporosis and atherosclerosis, which have linking these diseases. Evidence that osteoporosis, calcification of the aorta and heart valves, as well as atherosclerotic vascular disease are related pathological processes, are presented. It is emphasized that statins can favorably affect bone metabolism, and bisphosphonates, on the contrary, have a positive effect on the lipid profile. New approaches to prevention and treatment of osteoporosis based on use of combined drugs are discussed. Fosavans is one of these drugs, which combines powerful antiresorptive and anabolic aspects of osteoporosis therapy and contains the original alendronate at a dose of 70 mg and vitamin D3 at a dose of 2800 IU.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Veronika Shishkova

Әдебиет тізімі

  1. Braithwaite R.S., Col N.F., Wong J.B. Estimating hip fracture morbidity, mortality and costs. JAGS 2003; 51: 364-70.
  2. Wenger N.K. Coronary disease in women. Ann Rev Med 1985; 36: 285-94.
  3. Hamerman D. Bone health across the generations. A primer for health providers concerned with osteoporosis prevention. Maturitas 2004; 50: 1-7.
  4. Kiel D.P., Kauppila L.I., Cupples L.A., et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 2001; 68: 271-76.
  5. Frye M.A., Melton L.J., Bryant S.C., et al. Osteoporosis and calcification of the aorta. Bone Miner 1992; 19: 185-94.
  6. Schulz E., Arfai K., Liu X., Sayre J., Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89: 4246-53.
  7. Banks L.M., Macsweeney J.E., Stevenson J.C. Effect of degenerative spinal aortic calcification on bone density measurements in postmenopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest 1994; 24: 813-17.
  8. Barengolts E.L., Berman M., Kukreja S.C., et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998; 62: 209-13.
  9. Тот П., Мэки К. Нарушения липидного обмена. М., 2010.
  10. Kado D.M., Browner W.S., Blackwell T., Gove R., Cummings S.R. Rate of bone loss is associated with mortality in older women: A prospective study. J Bone Miner Res 2000; 15: 1974-80.
  11. Tankoґ L.B., Bagger Y.Z., Christiansen. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003; 73: 15-20.
  12. Browner W.S., Sooley D.G., Vogt T.M. Non-trauma mortality in eldery women with low bone mineral density. Lancet 1991; 338: 335-38.
  13. Browner W.S., Pressman A.R., Nevitt M.C., et al. Association between low density and stroke in eldery women. Stroke 1993; 24: 940-46.
  14. Uyama O., Yoshimoto Y., Yamamoto Y., Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997; 28: 1730-32.
  15. Van der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106: 273-78.
  16. Yamaguchi T., Sugimoto T., Yano S., et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002; 49: 211-17.
  17. Demer L.L. A skeleton in the atherosclerosis closet. Circulation 1995; 92: 2029-32.
  18. Doherty T.M., Fitzpatrick L.A., Inoue F., et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004; 25: 629-72.
  19. Rubin M.R., Silverberg S.J. Vascular calcification and osteoporosis - The nature of the nexus. J Clin Endocrinol Metab 2004; 89: 4243-45.
  20. Doherty T.M., Asotra K., Fitzpatrick L.A., et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003; 100: 11203-206.
  21. Frye M.A., Melton L.J. 3rd, Bryant S.C., et al. Osteoporosis and calcification of the aorta. Bone Miner 1992; 19: 185-94.
  22. Shanahan C.M., Сагу N.R., Metcalfe J.C., et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaque. J Clin Invest 1994; 93: 2393-402.
  23. Giachelli C.M., Bae N., Almeida M., et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaque. J Clin Invest 1993; 92: 1686-96.
  24. Bostrom К., Watson K.E., Hom S., et al. Bone morphogenic expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-09.
  25. Katsuda S., Okada Y., Minamoto T., et al. Collagens in human atherosclerosis. Arterioscler Thromb 1992; 12: 494-502.
  26. Parhami F., Morrow A.D., Balucan J., et al. Lipid oxidation oroducts have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation of the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17: 680-87.
  27. Witztum J.L., Steinberg D. Role of oxidized low density li poprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
  28. Pahmani F., Garfinkel A., Demer L.L. Role of li pids in osteoporosis. Arterioscler Thromb Vasc Biol 2000; 20: 2346-48.
  29. Watson K.E., Bostrom K., Ravindranath R., et al. TGF-beta and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994; 93: 2106-13.
  30. Nishizava Y., Morii H. Osteoporosis and atherosclerosis in chronic renal failure. Osteoporosis Int 1997; 7(3): S188-192.
  31. Stefenelli Т., Mayer H., Bergler-Klein J., et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993; 95: 197-202.
  32. Woods А., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.
  33. Libby P., Sukhova G., Lee R.T., et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovascular Pharmacol 1995; 25: S9-12.
  34. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficiency mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-68.
  35. Tintut Y., Patel J., Pahmani F., Demer L.L. Tumor necrosis factor- a promotes in vitro calcification of vascular cells via the camp pathway. Circulation 2000; 102: 2636-42.
  36. Welch G.N., Loscalzo J. Homocystein and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
  37. Browner W.S., Mallow M.R. Homocysteinemia and bone density in eldery women. Lancet 1991; 338: 1470.
  38. Werner N., Nickenig G., Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-16.
  39. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-49.
  40. Wang G.J., Chung K.C., Shen W.J. Li pid-clearing agents in steroid-induced osteoporosis. J Formos Med Ass 1995; 94: 589-92.
  41. Cui Q., Wang G.J., Su C.C., Balan G. The Otto Aufrance award: lovastatin prevents steroid induced adi pogenesis and osteonecrosis. Clin Ortop 1997; 344: 819.
  42. Bauer D.C., Mundy G.R., Jamal S.A., et al. Use of statins and fracture. Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Ann Intern Med 2004; 164: 146-52.
  43. Edwards CJ., Russell RGG., Spector DT. Statins and bone: myth or reality? Calcif Tissue Int 2001; 69: 63-6.
  44. Mundy G.R. Statins and their potential for osteoporosis. Bone 2001; 29: 495-97.
  45. Hennessy S., Strom B.L. Statins and fracture risk. JAMA 2001; 285: 1888-89.
  46. Cummings S.R., Bauer D.C. Do statins prevent both cardiovascular disease and fracture? JAMA 2000; 283: 3255-57.
  47. Adami S., Braga V., Guidi G., et al. Chronic intravenous aminobisphosphanate therapy increases high-density li poprotein cholesterol and decrease low-density cholesterol. J Bone Min Res 2000; 15: 599-604.
  48. Rogers M.J., Frith J.C., Luckman S.P., et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24: 73-9S.
  49. Maksymowych W.P. Bisphosphonates for arthritis. A confusing rationale. J Rheumatol 2003; 30: 430-33.
  50. Danenberg H.D., Golomb G., Groothuis A., et al. Liposomal alendronate inhibits systemic innate immunity and reduces in stent neointimal hyperplasia in rabbits. Circulation 2003; 108: 2798-804.
  51. Price PA., Faus SA., Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-24.
  52. Tanko L.B., Qin G., Alexandersen P., Bagger Y.Z., Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2004; 16: 184-90.
  53. Шишкова В.Н. Ожирение и остеопороз // Остеопороз и остеопатии 2011. № 1. С. 21-6

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2012

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>